Prof. Jean Bourhis - Fond'action contre le cancer
Jean Bourhis - Advisor at Nanobiotix | The Org
Category (en-gb) - GORTEC - GROUPE ONCOLOGIE RADIOTHERAPIE TETE ET COU
The FLASH Effect: Establishing a Path to Human Clinical Trials
Vers la fin des travaux du stade Jean-Bourhis
Salle-Jean-Bourhis - Trégourez
Debiopharm on Twitter: "Pr. Jean Bourhis, Head of Radio-Oncology at CHUV Lausanne and the lead of the study, shares his thoughts about IAP antagonist and chemo-radio-sensitizer #Debio1143 for #headandneckcancer #ESMO2019 https://t.co/Z3TXbHbpWe" /
Competence - «Wir hoffen, 2025 die ersten Patient:innen behandeln zu können»
Jean-Marie BOURHIS | Assistant Professor | PhD | Viral Replication Machinery | Research profile
Jean-Pierre LE BOURHIS | Senior Researcher | PhD in political science | French National Centre for Scientific Research, Paris | CNRS | CRAPE - Arenes | Research profile
Contre le cancer, des rayons très prometteurs | 24 heures
Jean Bourhis, ESMO 2019 - Debio 1143 in head and neck cancer - touchONCOLOGY
Première mondiale à Lausanne dans le traitement par radiothérapie | Radio Lac
The FLASH Effect: Establishing a Path to Human Clinical Trials
JEAN BOURHIS - ONCOBELL
Jean Bourhis — Wikipédia
Jean Bourhis – Chief of Radiation Oncology Service – CHUV / Centre hospitalier universitaire vaudois | LinkedIn
Prof. Jean Bourhis @CHUVLausanne #ESMO20 #headandneckcancer Results of the GORTEC 2015-01 “PembroRad” randomized trial
GORTEC: Cisplatin chemoradiation plus debio 1143 in patients with locally advanced head and neck squamous cell carcinoma - ecancer
Particle physics pushing cancer treatment boundaries | eNCA
Dr. Bourhis on the OS Benefit of Xevinapant Plus Chemoradiotherapy in HNSCC
An expert's insight on FLASH radiotherapy: Prof. Jean Bourhis, Chief or Radio-Oncology at CHUV - YouTube
Tribute to José Luis Pico | EBMT
Kährs Group Honored By Saint-Gobain for Corporate Social Responsibility | Wood Floor Business
